Halda Therapeutics Secures $126M in Series B Funding to Advance Next-Gen Oral TACs

Funding Amount:
Halda Therapeutics has raised $126 million in a Series B funding round.

Investors:
The funding round was supported by new investors including Deep Track Capital, Frazier Life Sciences, and RA Capital Management.

Purpose:
The funds will be used to bring next-generation oral TACs (tumor-associated antigens) to the clinic.

Clinical Focus:
The primary clinical focus is on metastatic castration-resistant prostate cancer.

Timeline:
The clinical study for metastatic castration-resistant prostate cancer is scheduled to begin in the next half of the year.

Biotech Landscape:
This funding highlights the ongoing interest in biotech innovations, particularly in the development of advanced treatments for cancer and other chronic conditions.